MCID: TRC022
MIFTS: 37

Tricuspid Valve Insufficiency

Categories: Cardiovascular diseases

Aliases & Classifications for Tricuspid Valve Insufficiency

MalaCards integrated aliases for Tricuspid Valve Insufficiency:

Name: Tricuspid Valve Insufficiency 12 44 15 73
Tricuspid Regurgitation 12 29 55 6
Tricuspid Valve Regurgitation 12
Tricuspid Incompetence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4080
MeSH 44 D014262
UMLS 73 C0040961

Summaries for Tricuspid Valve Insufficiency

Disease Ontology : 12 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal.

MalaCards based summary : Tricuspid Valve Insufficiency, also known as tricuspid regurgitation, is related to mitral valve disease and pulmonary valve disease. An important gene associated with Tricuspid Valve Insufficiency is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11). The drugs Rivaroxaban and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and lung, and related phenotypes are craniofacial and embryo

Related Diseases for Tricuspid Valve Insufficiency

Diseases in the Tricuspid Valve Disease family:

Tricuspid Valve Insufficiency

Diseases related to Tricuspid Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 mitral valve disease 29.5 CRELD1 FBN1
2 pulmonary valve disease 10.6 CRELD1 PTPN11
3 toxic myocarditis 10.6 NPPB ZIC3
4 cardiac tamponade 10.6 ACVRL1 NPPB
5 ebstein anomaly 10.5 CRELD1 NPPB
6 pulmonic stenosis 10.4 PTPN11 ZIC3
7 patent ductus arteriosus 1 10.3 CRELD1 NPPB PTPN11
8 mitral valve stenosis 10.3 ACVRL1 CRELD1 NPPB
9 heart septal defect 10.3 ACVRL1 CRELD1
10 constrictive pericarditis 10.2 ALB NPPB
11 aortic valve insufficiency 10.2 FBN1 NPPB
12 chylothorax, congenital 10.2 ALB PTPN11
13 syndrome of inappropriate antidiuretic hormone 10.2 ALB NPPB
14 noma 10.1 ALB PTPN11
15 renal hypertension 10.1 ALB NPPB
16 mitral valve insufficiency 10.0 CRELD1 FBN1 NPPB
17 arteries, anomalies of 9.9 ACVRL1 ALB NPPB
18 endocardial fibroelastosis 9.9
19 hypoplastic left heart syndrome 1 9.9
20 myocardial infarction 9.9
21 infantile liver failure syndrome 1 9.9
22 pulmonary hypertension 9.9
23 acute liver failure 9.9
24 hypoplastic left heart syndrome 9.9
25 protein-losing enteropathy 9.9
26 atrial heart septal defect 9.9
27 inferior myocardial infarction 9.9
28 pulmonary valve stenosis 9.9
29 situs inversus 9.9
30 pulmonary atresia with intact ventricular septum 9.8
31 hemopericardium 9.8
32 tricuspid valve prolapse 9.8
33 congenitally corrected transposition of the great arteries 9.8
34 double discordia 9.8
35 transposition of the great arteries 9.8
36 hydronephrosis 9.8 ALB ZIC3
37 tetralogy of fallot 9.7 CRELD1 FBN1 NPPB PTPN11
38 aortic valve disease 1 9.6 FBN1 NPPB
39 tricuspid valve stenosis 9.4 ARSE CA6 CRELD1 FBN1
40 heart disease 8.6 ALB CRELD1 FBN1 NPPB PTPN11 ZIC3
41 tricuspid valve disease 8.5 ACVRL1 ARSE CRELD1 FBN1 MC3R NPPB

Graphical network of the top 20 diseases related to Tricuspid Valve Insufficiency:



Diseases related to Tricuspid Valve Insufficiency

Symptoms & Phenotypes for Tricuspid Valve Insufficiency

MGI Mouse Phenotypes related to Tricuspid Valve Insufficiency:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.55 ACVRL1 CRELD1 FBN1 PTPN11 ZIC3
2 embryo MP:0005380 9.43 FBN1 PTPN11 SMG6 ZIC3 ACVRL1 CRELD1
3 normal MP:0002873 9.1 ACVRL1 ALB PAPPA PTPN11 SMG6 ZIC3

Drugs & Therapeutics for Tricuspid Valve Insufficiency

Drugs for Tricuspid Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivaroxaban Approved Phase 4 366789-02-8
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
4
Propafenone Approved Phase 4 54063-53-5 4932
5
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
6
Tolvaptan Approved Phase 4 150683-30-0 216237
7
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
8
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
9
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 77-92-9 311
10 Kava Approved, Investigational, Nutraceutical Phase 4,Not Applicable 9000-38-8
11 Anticoagulants Phase 4
12 Antithrombin III Phase 4
13 Antithrombins Phase 4
14 Factor Xa Inhibitors Phase 4
15 HIV Protease Inhibitors Phase 4
16
protease inhibitors Phase 4
17 Serine Proteinase Inhibitors Phase 4
18 Adrenergic Agents Phase 4,Phase 1
19 Adrenergic Antagonists Phase 4
20 Adrenergic beta-Antagonists Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Autonomic Agents Phase 4,Phase 1
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
26 Cytochrome P-450 CYP3A Inhibitors Phase 4
27 Cytochrome P-450 Enzyme Inhibitors Phase 4
28 Diuretics, Potassium Sparing Phase 4
29 Neurotransmitter Agents Phase 4,Phase 1
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Potassium Channel Blockers Phase 4
32 Sodium Channel Blockers Phase 4
33 Sympatholytics Phase 4
34 Vasodilator Agents Phase 4,Phase 2,Phase 1,Not Applicable
35 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2,Not Applicable
36 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
37 Sildenafil Citrate Phase 4,Phase 2,Not Applicable 171599-83-0
38 Antihypertensive Agents Phase 4,Phase 3,Phase 2
39 Arginine Vasopressin Phase 4
40 diuretics Phase 4
41 Hormones Phase 4
42 Natriuretic Agents Phase 4
43 Sodium Potassium Chloride Symporter Inhibitors Phase 4
44 Torsemide Phase 4
45 Vasopressins Phase 4
46 Calcium, Dietary Phase 4
47 Chelating Agents Phase 4
48 Citrate Nutraceutical Phase 4,Phase 2,Not Applicable
49
Iodine Approved, Investigational Phase 3 7553-56-2 807
50
Treprostinil Approved, Investigational Phase 3 81846-19-7 54786 6918140

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation Unknown status NCT02024230 Phase 4 Warfarin or Rivaroxaban
2 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
3 Tricuspid Regurgitation Study Completed NCT01093001 Phase 4
4 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
5 Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction Completed NCT02133352 Phase 4 Ranolazine
6 Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
7 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension Completed NCT01642407 Phase 4 Sildenafil
8 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER) Recruiting NCT02339974 Phase 4
9 BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement Terminated NCT00929474 Phase 4
10 Minimally Invasive Transthoracic Device Closure in Perimembranous Ventricular Septal Defect Unknown status NCT02644330 Phase 2, Phase 3
11 Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network Completed NCT00115934 Phase 3
12 Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) Completed NCT00147199 Phase 3 Inhaled treprostinil;Placebo inhalation solution
13 Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride Not yet recruiting NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
14 NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients Completed NCT00809094 Phase 2 N-acetylcysteine (NAC);Placebo
15 LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction Completed NCT00887588 Phase 2 LCZ696;Valsartan;Placebo
16 The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis Completed NCT00630864 Phase 2 Fx-1006A
17 Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System Recruiting NCT03331380 Phase 1, Phase 2
18 A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism Recruiting NCT03108833 Phase 2 Recombinant Human Prourokinase;Alteplase
19 Preventive Approach to Congenital Heart Block With Hydroxychloroquine Recruiting NCT01379573 Phase 2 Hydroxychloroquine
20 Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) Recruiting NCT03525418 Phase 1, Phase 2
21 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension Recruiting NCT02951429 Phase 2 Pirfenidone;Placebo;Sildenafil
22 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Recruiting NCT03274076 Phase 1, Phase 2 Tofacitinib;Placebo Oral Tablet
23 Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Not yet recruiting NCT03466333 Phase 2 Enalapril Maleate;Placebo oral capsule
24 A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis Terminated NCT01629667 Phase 2
25 Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™ Completed NCT02098200 Phase 1
26 Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease Completed NCT01895998 Phase 1 Albuterol
27 Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study Completed NCT01571037 Phase 1 Inhaled, nebulized, Milrinone;inhaled nebulized milrinone
28 Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers Completed NCT01673555 Phase 1 GSK1278863;Placebo
29 Study of GSK2586881 on Acute Hypoxia and Exercise Recruiting NCT03000686 Phase 1
30 Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome Recruiting NCT02398604 Phase 1 Allo-hMSCs;Placebo
31 Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. Not yet recruiting NCT03406884 Phase 1 c-kit+ cells;Placebo
32 Ring Versus Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases Unknown status NCT02721524 Not Applicable
33 Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart Unknown status NCT01444222
34 Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL) Unknown status NCT02387697 Not Applicable
35 Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery Unknown status NCT01580436 Not Applicable
36 The Impact of Right Ventricular Pacing on Tricuspid Regurgitation Unknown status NCT00419354
37 Long-term Outcome After Isolated Tricuspid Valve Repair Unknown status NCT01537458
38 Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients Unknown status NCT00772135 Not Applicable sildenafil citrate
39 Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ? Unknown status NCT01947257 Not Applicable
40 Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease Unknown status NCT00434902
41 Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation Completed NCT01246947 Not Applicable
42 Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation Completed NCT01203137
43 The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease Completed NCT01246141
44 EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty Completed NCT01532921
45 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial Completed NCT01585779
46 Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients Completed NCT01023451
47 Acute Normovolemic Hemodilution on Serum-creatinine Concentration in Cardiac Surgery Completed NCT02831270 hydroxyethyl starch (HES 130/0.6)
48 Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery Completed NCT02502448 Not Applicable hydroxyethyl starch (HES 130/0.6)
49 Long Term Effects of Erythrocyte Lysis Completed NCT00842621
50 Coenzyme Q-10 and Pulmonary Arterial Hypertension Completed NCT01148836 Not Applicable

Search NIH Clinical Center for Tricuspid Valve Insufficiency

Cochrane evidence based reviews: tricuspid valve insufficiency

Genetic Tests for Tricuspid Valve Insufficiency

Genetic tests related to Tricuspid Valve Insufficiency:

# Genetic test Affiliating Genes
1 Tricuspid Regurgitation 29

Anatomical Context for Tricuspid Valve Insufficiency

MalaCards organs/tissues related to Tricuspid Valve Insufficiency:

41
Heart, Brain, Lung, Liver, Testes

Publications for Tricuspid Valve Insufficiency

Articles related to Tricuspid Valve Insufficiency:

(show all 23)
# Title Authors Year
1
A systematic method for using 3D echocardiography to evaluate tricuspid valve insufficiency in hypoplastic left heart syndrome. ( 25298694 )
2014
2
Surgical treatment of tricuspid valve insufficiency promotes early reverse remodeling in patients with axial-flow left ventricular assist devices. ( 21839483 )
2012
3
Pulmonary arterial pressure and right ventricular dilatation independently determine tricuspid valve insufficiency severity in pre-capillary pulmonary hypertension. ( 23409355 )
2012
4
Recurrent protein-losing enteropathy and tricuspid valve insufficiency in a transplanted heart: a causal relationship? ( 21801319 )
2012
5
The clover technique for the treatment of complex tricuspid valve insufficiency: midterm clinical and echocardiographic results in 66 patients. ( 20117940 )
2010
6
Retrospective analysis of stage I Norwood procedures with tricuspid valve insufficiency in the past 5 years. ( 17669787 )
2007
7
Cardiac bullet embolus after thoracic vena cava penetrating injury causing tricuspid valve insufficiency. ( 17386917 )
2007
8
Acute liver failure as the first manifestation of severe traumatic tricuspid valve insufficiency. ( 16432673 )
2006
9
Diagnosis and treatment of traumatic tricuspid valve insufficiency. ( 14642061 )
2003
10
Traumatic tricuspid valve insufficiency: case report. ( 11499605 )
2001
11
Post-traumatic tricuspid valve insufficiency. 2 cases of delayed clinical manifestation. ( 9339514 )
1997
12
Fetal and transient neonatal right heart dilatation with severe tricuspid valve insufficiency in association with abnormally S-shaped kinking of the ductus arteriosus. ( 7614140 )
1995
13
Repair of traumatic tricuspid valve insufficiency by trabecular muscle elevation. ( 7887723 )
1995
14
Traumatic tricuspid valve insufficiency. Experience in thirteen patients. ( 7967672 )
1994
15
Tricuspid valve insufficiency as a complication of endomyocardial biopsy. ( 14621794 )
1992
16
Endocardial fibroelastosis and tricuspid valve insufficiency in a calf. ( 3610756 )
1987
17
Repair of tricuspid valve insufficiency in patients undergoing double (aortic and mitral) valve replacement. Perioperative mortality and long-term (1 to 20 years) follow-up in 109 patients. ( 3669702 )
1987
18
Transient tricuspid valve insufficiency following acute inferior myocardial infarction. ( 3485873 )
1986
19
Management of tricuspid valve insufficiency. Replacement with Hancock bioprosthesis or suture annuloplasty. ( 511908 )
1979
20
"Balloon valvulotomy" of congenital pulmonary valve stenosis with tricuspid valve insufficiency. ( 519671 )
1979
21
Dynamic tricuspid valve insufficiency produced by a right ventricular thrombus from a pacemaker. ( 699661 )
1978
22
[D-transposition in situs inversus, atrial septal defect, open foramen ovale and tricuspid valve insufficiency]. ( 997709 )
1976
23
An interventricular septal defect and a tricuspid valve insufficiency in a trotter mare. ( 4426317 )
1974

Variations for Tricuspid Valve Insufficiency

ClinVar genetic disease variations for Tricuspid Valve Insufficiency:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh37 Chromosome 12, 112888168: 112888168
2 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh38 Chromosome 12, 112450364: 112450364
3 46;XX;ins(5;6)(p13;p24p25)dn Translocation Pathogenic
4 46;XX;inv(14)(q24.1q32.1)dn inversion Uncertain significance
5 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh38 Chromosome 16, 15724166: 15724166
6 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh37 Chromosome 16, 15818023: 15818023

Expression for Tricuspid Valve Insufficiency

Search GEO for disease gene expression data for Tricuspid Valve Insufficiency.

Pathways for Tricuspid Valve Insufficiency

GO Terms for Tricuspid Valve Insufficiency

Biological processes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.13 ALB FBN1 PAPPA
2 regulation of blood pressure GO:0008217 8.8 ACVRL1 MC3R NPPB

Sources for Tricuspid Valve Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....